Optimizing finasteride chemoprevention

Comment

Nick Groves-Kirkby. Nat Rev Urol. 2010 Apr.

. 2010 Apr;7(4):178.

doi: 10.1038/nrurol.2010.33.

No abstract available

Comment on

Finasteride to prevent prostate cancer: should all men or only a high-risk subgroup be treated?
Vickers AJ, Savage CJ, Lilja H. Vickers AJ, et al. J Clin Oncol. 2010 Mar 1;28(7):1112-6. doi: 10.1200/JCO.2009.23.5572. Epub 2010 Feb 1. J Clin Oncol. 2010. PMID: 20124185 Free PMC article.

The cost of prostate cancer chemoprevention: a decision analysis model.
Svatek RS, Lee JJ, Roehrborn CG, Lippman SM, Lotan Y. Svatek RS, et al. Cancer Epidemiol Biomarkers Prev. 2006 Aug;15(8):1485-9. doi: 10.1158/1055-9965.EPI-06-0221. Cancer Epidemiol Biomarkers Prev. 2006. PMID: 16896037
A review of phase III clinical trials of prostate cancer chemoprevention.
Thorpe JF, Jain S, Marczylo TH, Gescher AJ, Steward WP, Mellon JK. Thorpe JF, et al. Ann R Coll Surg Engl. 2007 Apr;89(3):207-11. doi: 10.1308/003588407X179125. Ann R Coll Surg Engl. 2007. PMID: 17394699 Free PMC article. Review.
Chemoprevention of prostate cancer with finasteride.
Canby-Hagino ED, Brand TC, Hernandez J, Thompson IM. Canby-Hagino ED, et al. Expert Opin Pharmacother. 2006 May;7(7):899-905. doi: 10.1517/14656566.7.7.899. Expert Opin Pharmacother. 2006. PMID: 16634712 Review.
The person-years saved model and other methodologies for assessing the population impact of cancer-prevention strategies.
Unger JM, LeBlanc M, Thompson IM, Coltman CA Jr. Unger JM, et al. Urol Oncol. 2004 Jul-Aug;22(4):362-8. doi: 10.1016/j.urolonc.2004.04.009. Urol Oncol. 2004. PMID: 15283898
Cost-effectiveness of prostate cancer chemoprevention: a quality of life-years analysis.
Svatek RS, Lee JJ, Roehrborn CG, Lippman SM, Lotan Y. Svatek RS, et al. Cancer. 2008 Mar 1;112(5):1058-65. doi: 10.1002/cncr.23276. Cancer. 2008. PMID: 18186497